Spyre Therapeutics, Inc.

NasdaqGS:SYRE Rapporto sulle azioni

Cap. di mercato: US$1.7b

Spyre Therapeutics Dividendo

Dividendo criteri di controllo 0/6

Spyre Therapeutics does not have a record of paying a dividend.

Informazioni chiave

n/a

Rendimento del dividendo

-5.2%

Rendimento del riacquisto

Rendimento totale per gli azionisti-5.2%
Rendimento futuro dei dividendin/a
Crescita dei dividendin/a
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Rapporto di remunerazionen/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Oct 01

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09
Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aeglea BioTherapeutics EPS misses by $0.14

May 10

Aeglea completes patient randomization in late-stage pegzilarginase trial

May 03

What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition

Mar 17
What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Insufficient data to determine if SYRE's dividends per share have been stable in the past.

Dividendo in crescita: Insufficient data to determine if SYRE's dividend payments have been increasing.


Rendimento dei dividendi rispetto al mercato

Spyre Therapeutics Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di SYRE rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (SYRE)n/a
Fondo del 25% del mercato (US)1.5%
Top 25% del mercato (US)4.5%
Media del settore (Biotechs)2.2%
Analista previsionale (SYRE) (fino a 3 anni)n/a

Dividendo notevole: Unable to evaluate SYRE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividendo elevato: Unable to evaluate SYRE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Distribuzione degli utili agli azionisti

Copertura degli utili: Insufficient data to calculate SYRE's payout ratio to determine if its dividend payments are covered by earnings.


Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Unable to calculate sustainability of dividends as SYRE has not reported any payouts.


Scoprire le società che pagano dividendi forti